ScoreWhy is Blueprint Medicines Corp. ?
1
With a growth in Net Sales of 2.08%, the company declared Very Positive results in Mar 25
- The company has declared positive results for the last 5 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -145.55 MM
- ROCE(HY) Highest at -47.71%
- RAW MATERIAL COST(Y) Fallen by -3.82% (YoY)
2
Rising Promoter Confidence
- Promoters have increased their stake in the company by 1.63% over the previous quarter and currently hold 2.19% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Blueprint Medicines Corp. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Blueprint Medicines Corp. for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Blueprint Medicines Corp.
13.2%
0.48
50.80%
S&P 500
13.22%
0.80
20.19%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
50.85%
EBIT Growth (5y)
9.12%
EBIT to Interest (avg)
-70.96
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.21
Sales to Capital Employed (avg)
0.34
Tax Ratio
1.19%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
11.58%
ROE (avg)
4.64%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
24.13
EV to EBIT
-47.78
EV to EBITDA
-52.59
EV to Capital Employed
20.12
EV to Sales
14.82
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-42.10%
ROE (Latest)
-45.52%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend30What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -145.55 MM
ROCE(HY)
Highest at -47.71%
RAW MATERIAL COST(Y)
Fallen by -3.82% (YoY
NET SALES(Q)
Highest at USD 149.41 MM
OPERATING PROFIT(Q)
Highest at USD -36.63 MM
OPERATING PROFIT MARGIN(Q)
Highest at -24.51 %
PRE-TAX PROFIT(Q)
Highest at USD 1.28 MM
NET PROFIT(Q)
Highest at USD 0.5 MM
-3What is not working for the Company
INTEREST(9M)
At USD 54.74 MM has Grown at 26.67%
DEBT-EQUITY RATIO
(HY)
Highest at 40.07 %
Here's what is working for Blueprint Medicines Corp.
Operating Cash Flow
Highest at USD -145.55 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD 1.28 MM has Grown at 102.15%
over average net sales of the previous four periods of USD -59.88 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 0.5 MM has Grown at 100.83%
over average net sales of the previous four periods of USD -60.1 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Highest at USD 149.41 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Sales
At USD 149.41 MM has Grown at 17.46%
over average net sales of the previous four periods of USD 127.21 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD -36.63 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at -24.51 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 1.28 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 0.5 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Raw Material Cost
Fallen by -3.82% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Blueprint Medicines Corp.
Interest
At USD 54.74 MM has Grown at 26.67%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at 40.07 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Non Operating Income
Highest at USD 46.83 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
